Page 111 - Drug Class Review
P. 111
Drug Effectiveness Review Project
Drugs Authors and year: Feldman et al. 2001; 40, 93 Gauthier et al. 2002; 71 Gauthier et al. 2002; 72 Feldman Country: Multinational (Canada, Australia, France) Eisai, Inc. and Pfizer, Inc. To examine the efficacy and safety of DON in patients with moderate to severe AD; subgroup analyses focus on behavioral symptoms and patients with moderate severity Setting: Multi-center (32) placebo donepezil N/A 5-10 mg/d 24 weeks 24 weeks 146 144 All of the following criteria: probable or possible AD according to DSM-IV and the NINCDS; a screening standardized MMSE score of 5-17
Alzheimer et al. 2003 73 Study design: RCT Sample size: 290 system disease investigational drugs
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
